{
  "id": 7550148,
  "title": "Kymera Therapeutics at Morgan Stanley conference: oral degrader push",
  "url": "https://urgent.news/2026/09/15/kymera-therapeutics-at-morgan-stanley-conference-oral-degrader-push",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T12:40:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/kymera-therapeutics-at-morgan-stanley-conference-oral-degrader-push-93CH-4901713"
  },
  "original_language": "en",
  "account": null,
  "summary": "Kymera Therapeutics (KYMR) highlighted strong early clinical data and a broad pipeline during its presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on 15 September 2026. The company's main focus is on KT-621, an oral STAT6 degrader aimed at atopic dermatitis and later at asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. Kymera is also developing KT-579, an oral IRF5 degrader for lupus and other autoimmune diseases, and KT-485, a second-generation IRAK4 degrader in partnership with Sanofi. The company expects key readouts in late 2024 for KT-579 and KT-621, with asthma data from BREADTH due in 2027.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}